Donoghue Forlines’s BridgeBio Pharma BBIO Stock Holding History

Donoghue Forlines’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-24,712	Closed	-$1.76M	–	216
2020 Q4	$1.76M	Buy	+24,712	New	+$1.19M	0.34%	46

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SUT

SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Donoghue Forlines's BBIO Position: Q1 2021 in Review

Donoghue Forlines sold out of BridgeBio Pharma (BBIO) in Q1 2021, closing a stake of 24,712 shares — an estimated $1.76M sold.

Donoghue Forlines first reported a position in BBIO in Q4 2020 and held it in 1 quarter. The position peaked at $1.76M in Q4 2020. 198 funds tracked by Wall St. Rank hold BBIO as of Q1 2021.

Donoghue Forlines reported no remaining BridgeBio Pharma position as of Q1 2021 after selling out during the quarter.
Donoghue Forlines sold 24,712 BridgeBio Pharma shares in Q1 2021, an estimated $1.76M.
Donoghue Forlines first reported a position in BridgeBio Pharma in Q4 2020 and held it in 1 quarter.
Donoghue Forlines's BridgeBio Pharma position peaked at $1.76M in Q4 2020.
198 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2021.

Based on Donoghue Forlines's 13F filing for Q1 2021, filed 14 May 2021.